Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment.


Journal

JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073

Informations de publication

Date de publication:
07 03 2019
Historique:
received: 21 05 2018
accepted: 25 01 2019
pubmed: 8 2 2019
medline: 2 6 2020
entrez: 8 2 2019
Statut: epublish

Résumé

Epithelial ovarian cancer (EOC) often presents with metastases and ascites. Granulocytic myeloid-derived suppressor cells are an immature population that impairs antitumor immunity. Since suppressive granulocytes in the ascites of patients with newly diagnosed EOC were morphologically mature, we hypothesized that PMN were rendered suppressive in the tumor microenvironment (TME). Circulating PMN from patients were not suppressive but acquired a suppressor phenotype (defined as ≥1 log10 reduction of anti-CD3/CD28-stimulated T cell proliferation) after ascites supernatant exposure. Ascites supernatants (20 of 31 supernatants) recapitulated the suppressor phenotype in PMN from healthy donors. T cell proliferation was restored with ascites removal and restimulation. PMN suppressors also inhibited T cell activation and cytokine production. PMN suppressors completely suppressed proliferation in naive, central memory, and effector memory T cells and in engineered tumor antigen-specific cytotoxic T lymphocytes, while antigen-specific cell lysis was unaffected. Inhibition of complement C3 activation and PMN effector functions, including CR3 signaling, protein synthesis, and vesicular trafficking, abrogated the PMN suppressor phenotype. Moreover, malignant effusions from patients with various metastatic cancers also induced the C3-dependent PMN suppressor phenotype. These results point to PMN impairing T cell expansion and activation in the TME and the potential for complement inhibition to abrogate this barrier to antitumor immunity.

Identifiants

pubmed: 30730851
pii: 122311
doi: 10.1172/jci.insight.122311
pmc: PMC6483507
doi:
pii:

Substances chimiques

CD28 Antigens 0
Complement C3 0
Cytokines 0
Muromonab-CD3 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NCI NIH HHS
ID : P50 CA159981
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016056
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA108456
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA188900
Pays : United States
Organisme : NLM NIH HHS
ID : K01 LM012100
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA085183
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA164333
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA172105
Pays : United States

Références

J Immunol. 2011 Jul 1;187(1):391-400
pubmed: 21642540
Oncotarget. 2017 Apr 5;8(31):51008-51015
pubmed: 28881624
Nature. 2015 Dec 17;528(7582):413-7
pubmed: 26649828
Proc Natl Acad Sci U S A. 2004 May 4;101(18):7076-81
pubmed: 15118085
Nat Immunol. 2018 Feb;19(2):108-119
pubmed: 29348500
J Clin Invest. 2012 Jan;122(1):327-36
pubmed: 22156198
Clin Exp Immunol. 2014 Oct;178(1):142-53
pubmed: 24853370
J Clin Oncol. 2015 Dec 1;33(34):4015-22
pubmed: 26351349
Oncoimmunology. 2018 Mar 6;7(6):e1438108
pubmed: 29872581
J Immunol. 2016 Feb 1;196(3):1412-8
pubmed: 26718342
Oncotarget. 2015 May 10;6(13):11310-26
pubmed: 25888637
J Clin Invest. 2014 Dec;124(12):5466-80
pubmed: 25384214
Cancer Cell. 2016 Jun 13;29(6):832-845
pubmed: 27265504
Sci Rep. 2018 Feb 16;8(1):3135
pubmed: 29453429
Blood. 2003 Jun 1;101(11):4322-32
pubmed: 12560239
Oncoimmunology. 2017 Dec 26;7(4):e1412029
pubmed: 29632724
Sci Rep. 2015 Oct 08;5:14896
pubmed: 26447332
Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4221-6
pubmed: 24591638
PLoS One. 2015 Mar 23;10(3):e0121546
pubmed: 25799053
Ann Oncol. 2019 Jul 1;30(7):1080-1087
pubmed: 31046082
Cell Rep. 2018 Sep 4;24(10):2784-2794
pubmed: 30184510
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Gynecol Oncol. 2015 Jun;137(3):401-5
pubmed: 25839911
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
Nat Rev Immunol. 2018 Jan;18(1):5-18
pubmed: 28920587
Immunol Rev. 2016 Sep;273(1):329-43
pubmed: 27558344
Nat Med. 2007 Jul;13(7):828-35
pubmed: 17603493
Eur J Clin Invest. 2015 Apr;45(4):423-40
pubmed: 25678219
Blood. 2017 Jun 8;129(23):3100-3110
pubmed: 28416510
Oncoimmunology. 2017 Aug 16;6(11):e1356965
pubmed: 29147615
Front Immunol. 2017 Nov 23;8:1586
pubmed: 29218045
J Exp Med. 2019 Jan 7;216(1):176-194
pubmed: 30567719
Gynecol Oncol. 2016 Nov;143(2):241-245
pubmed: 27615398
J Proteomics. 2017 Mar 22;157:33-39
pubmed: 28188862
J Immunol. 2005 Feb 15;174(4):2084-91
pubmed: 15699138
J Immunol. 2017 May 15;198(10):4129-4139
pubmed: 28356386
J Innate Immun. 2013;5(3):277-89
pubmed: 23363774
Cell Rep. 2014 Mar 27;6(6):1085-1095
pubmed: 24613353
J Leukoc Biol. 2014 Nov;96(5):685-93
pubmed: 24929004
Cancer Cell. 2018 Oct 8;34(4):561-578.e6
pubmed: 30300579
Cancer Res. 2001 Jun 15;61(12):4756-60
pubmed: 11406548
Immunol Rev. 2016 Sep;273(1):121-39
pubmed: 27558332
Cancer Res. 2011 Dec 15;71(24):7463-70
pubmed: 22025564
Cell Physiol Biochem. 2017;41(6):2411-2418
pubmed: 28467978
Gut. 2018 Jun;67(6):1112-1123
pubmed: 29196437
Cell. 2017 Aug 24;170(5):927-938.e20
pubmed: 28841418
J Exp Med. 1975 Jun 1;141(6):1442-7
pubmed: 165258
Cancer Immunol Res. 2016 Apr;4(4):303-11
pubmed: 26817996
Clin Immunol. 2016 Oct;171:32-35
pubmed: 27546448
Blood. 2012 May 24;119(21):4963-70
pubmed: 22498738
Br J Cancer. 2019 Jan;120(2):207-217
pubmed: 30518816
Biochim Biophys Acta. 1999 Oct 13;1452(1):46-59
pubmed: 10525159
Gynecol Oncol. 2017 Sep;146(3):491-497
pubmed: 28624153
Mol Cell Proteomics. 2014 Dec;13(12):3558-71
pubmed: 25271300
Oncoimmunology. 2017 Jun 8;6(9):e1326442
pubmed: 28932632
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
pubmed: 16344461
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
Cancer Discov. 2017 Jul;7(7):694-703
pubmed: 28288993
Cell Rep. 2015 Feb 3;10(4):562-73
pubmed: 25620698
Front Immunol. 2017 Nov 20;8:1602
pubmed: 29209332
Neoplasma. 2013;60(5):546-52
pubmed: 23790174
J Immunol. 2009 May 1;182(9):5693-701
pubmed: 19380816
Nature. 2015 Jun 18;522(7556):345-348
pubmed: 25822788
Ann Oncol. 2013 Mar;24(3):679-87
pubmed: 23041585
Am J Respir Cell Mol Biol. 2018 Apr;58(4):492-499
pubmed: 29141155
Front Oncol. 2017 Feb 22;7:24
pubmed: 28275576
Front Immunol. 2016 Apr 14;7:137
pubmed: 27148258
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
J Immunol. 2013 Apr 1;190(7):3207-15
pubmed: 23455505
Immunology. 2001 Aug;103(4):465-72
pubmed: 11529937
Mol Cell Proteomics. 2018 Feb;17(2):270-289
pubmed: 29141914
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80
pubmed: 20385810
Neoplasia. 2012 Nov;14(11):994-1004
pubmed: 23226093
J Leukoc Biol. 2011 May;89(5):721-7
pubmed: 21330347
JCI Insight. 2017 May 4;2(9):
pubmed: 28469081
Gynecol Oncol. 2015 Aug;138(2):352-7
pubmed: 26001328
Immunity. 2013 Sep 19;39(3):611-21
pubmed: 24012420
Cancer Immunol Res. 2018 Feb;6(2):236-247
pubmed: 29301753
Oncoimmunology. 2016 Sep 13;5(11):e1232221
pubmed: 27999744
Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):E415-24
pubmed: 23271806

Auteurs

Kelly L Singel (KL)

Department of Immunology.

Tiffany R Emmons (TR)

Department of Immunology.

Anm Nazmul H Khan (ANH)

Department of Internal Medicine, and.

Paul C Mayor (PC)

Department of Surgery, Division of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.

Shichen Shen (S)

New York State Center of Excellence Bioinformatics and Life Sciences, University at Buffalo, Buffalo, New York, USA.

Jerry T Wong (JT)

Department of Pathology and Laboratory Medicine and.

Kayla Morrell (K)

Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.

Kevin H Eng (KH)

Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.

Jaron Mark (J)

Department of Surgery, Division of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.

Richard B Bankert (RB)

Department of Microbiology and Immunology, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, USA.

Junko Matsuzaki (J)

Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.

Richard C Koya (RC)

Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.

Anna M Blom (AM)

Division of Medical Protein Chemistry, Department of Translational Medicine, Lund University, Malmö, Sweden.

Kenneth R McLeish (KR)

Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky, USA.

Jun Qu (J)

New York State Center of Excellence Bioinformatics and Life Sciences, University at Buffalo, Buffalo, New York, USA.

Sanjay Ram (S)

Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

Kirsten B Moysich (KB)

Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.

Scott I Abrams (SI)

Department of Immunology.

Kunle Odunsi (K)

Department of Surgery, Division of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.

Emese Zsiros (E)

Department of Surgery, Division of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.

Brahm H Segal (BH)

Department of Immunology.
Department of Internal Medicine, and.
Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH